Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02460991 · ClinicalTrials.gov registry record · Phase 3
A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma
A Phase 3 study, sponsored by Boston Scientific Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2
- Enrollment target
NCT02460991: Clinical Trial Phase 3 study, sponsored by Boston Scientific Corporation.
NCT02460991 is a Phase 3 study that was terminated before completion, run by Boston Scientific Corporation. The registered enrollment target is 2 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02460991, a Phase 3 study, was terminated before completion, sponsored by Boston Scientific Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a prospective, multicenter study that will be conducted at up to 40 centers in the United States and Outside United States (OUS). Participants in the study will be randomly assigned to receive either ONCO-DOX or sorafenib treatment. This study will evaluate the study participants' outcomes (medical condition) after being treated with ONCO-DOX and compare it to those treated with sorafenib alone.
Primary Outcome
Overall survival in HCC subjects with minimum follow-up of subjects to at least one year
Interventions
- DRUG Sorafenib
- DEVICE DEB-TACE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-06-05 |
| Phase | Phase 3 |
Why NCT02460991 stopped before completion
NCT02460991 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT02460991 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02460991 about?
NCT02460991 is a clinical study titled "A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma". This is a prospective, multicenter study that will be conducted at up to 40 centers in the United States and Outside United States (OUS). Participants in the study will be randomly assigned to receive either ONCO-DOX or sorafenib treatment. This study will evaluate the study participants' outcomes (...
What is the current status of trial NCT02460991?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2015-11. Estimated completion is 2017-06-05.
What interventions are being tested in trial NCT02460991?
The interventions under investigation include: Sorafenib (DRUG), DEB-TACE (DEVICE).
Who is sponsoring clinical trial NCT02460991?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02460991's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia